Casey Community Outreach Program
After receiving a free eye exam at an OHSU Casey Community Outreach Program mobile clinic in Newberg on Sept. 19, 2020, Agatha Castle tries on a free pair of with the help of volunteer Zachary Urdang, M.D., Ph.D., who is also an OHSU surgical resident. (OHSU)
BRILLIANCE trial
Carlene Knight undergoes an eye exam by Mark Pennesi, M.D., Ph.D., at Oregon Health & Science Universitys Casey Eye Institute on April 29, 2021. As a participant in the BRILLIANCE clinical trial, Knight received an experimental gene-editing treatment that aims to improve eye sight. (OHSU/Josh Andersen)
BRILLIANCE trial
: Carlene Knight undergoes an eye exam by Mark Pennesi, M.D., Ph.D., at Oregon Health & Science Universitys Casey Eye Institute on April 29, 2021. As a participant in the BRILLIANCE clinical trial, Knight received an experimental gene-editing treatment that aims to improve eye sight. (OHSU/Josh Andersen)
BRILLIANCE trial
Carlene Knight, who was born with a gene mutation that has caused her to be legally blind, looks up to the sky while sitting outside Oregon Health & Science Universitys Casey Eye Institute on April 29, 2021. As a participant in the BRILLIANCE clinical trial, Knight received an experimental gene-editing treatment that is designed to repair the mutation and improve eye sight. (OHSU/Josh Andersen)
BRILLIANCE trial
Carlene Knight, who was born with a gene mutation that has caused her to be legally blind, smiles while sitting outside Oregon Health & Science Universitys Casey Eye Institute on April 29, 2021. As a participant in the BRILLIANCE clinical trial, Knight received an experimental gene-editing treatment that aims to improve eye sight. (OHSU/Josh Andersen)
BRILLIANCE trial
Mark Pennesi, M.D., Ph.D., who leads OHSU's involvement in the trial, center right, looks on as staff at Oregon Health & Science University's Casey Eye Institute perform the first-ever in vivo CRISPR gene edit procedure for the BRILLIANCE clinical trial. The study uses the gene-editing technology CRISPR to repair mutations in the CEP290 gene that cause a rare form of inherited blindness called Leber congenital amaurosis type 10. The trial is sponsored by Allergan plc. and Editas Medicine. (OHSU/Kristyna Wentz-Graff)
Benjamin Sivyer, Ph.D. (OHSU)
Mitchell Brinks, M.D. (OHSU)
Oregon Vision Health Network clinic
Gladys Rivera, One Community Health’s director of preventive health on Fri., Nov. 12, 2021. (OHSU/Christine Torres Hicks)
Oregon Vision Health Network clinic
Gisela Ayala at the One Community Health eye clinic in Hood River on Fri., Nov. 12, 2021. (OHSU/Christine Torres Hicks)